[96a5a0]: / output / allTrials / identified / NCT00003160_identified.json

Download this file

581 lines (581 with data), 28.2 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
{
"info": {
"nct_id": "NCT00003160",
"official_title": "A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Patients With Taxol/Platinum-Refractory Stage III and IV Ovarian Cancer",
"inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV ovarian cancer that is refractory to an initial chemotherapy regimen that included a platinum agent plus paclitaxel - Epithelial ovarian cancer - Primary carcinoma of the peritoneum - Fallopian tube cancer Initial response to platinum and paclitaxel must have been one of the following: Progression or stable disease Response that lasted less than 3 months Response that lasted at least 3 months, but when retreated with both agents (in combination or as single agents) disease was refractory Measurable or evaluable disease Evaluable disease is defined by: CA-125 at least 100 units/mL AND CA-125 level must have at least doubled from baseline determination\n\nPATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST or ALT no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No New York Heart Association Class III or IV heart disease No myocardial infarction within last 6 months No congestive heart failure No unstable angina No clinically significant pericardial effusion or arrhythmia Neurology: No current peripheral neuropathy of any etiology that is greater than grade 1 Other: No active serious infection or other serious underlying medical condition No prior significant allergic reactions to drugs containing Cremophor, such as teniposide, cyclosporin, or vitamin K Not pregnant or nursing Adequate contraception required of all fertile patients\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since immunotherapy No concurrent immunotherapy Chemotherapy: Prior paclitaxel treatment must have been administered on a 3 week or greater schedule No other prior chemotherapy besides platinum and paclitaxel At least 3 weeks since acceptable chemotherapy Endocrine therapy: At least 3 weeks since hormonal therapy No concurrent hormonal therapy Radiotherapy: At least 3 weeks since radiotherapy No prior radiation to greater than 30% of bone marrow Surgery: At least 3 weeks since major surgery"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV ovarian cancer that is refractory to an initial chemotherapy regimen that included a platinum agent plus paclitaxel - Epithelial ovarian cancer - Primary carcinoma of the peritoneum - Fallopian tube cancer Initial response to platinum and paclitaxel must have been one of the following: Progression or stable disease Response that lasted less than 3 months Response that lasted at least 3 months, but when retreated with both agents (in combination or as single agents) disease was refractory Measurable or evaluable disease Evaluable disease is defined by: CA-125 at least 100 units/mL AND CA-125 level must have at least doubled from baseline determination",
"criterions": [
{
"exact_snippets": "Histologically confirmed stage III or IV ovarian cancer",
"criterion": "ovarian cancer",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"III",
"IV"
]
},
{
"requirement_type": "confirmation",
"expected_value": "histologically"
}
]
},
{
"exact_snippets": "refractory to an initial chemotherapy regimen that included a platinum agent plus paclitaxel",
"criterion": "chemotherapy regimen",
"requirements": [
{
"requirement_type": "refractory",
"expected_value": true
},
{
"requirement_type": "components",
"expected_value": [
"platinum agent",
"paclitaxel"
]
}
]
},
{
"exact_snippets": "Epithelial ovarian cancer",
"criterion": "epithelial ovarian cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Primary carcinoma of the peritoneum",
"criterion": "primary carcinoma of the peritoneum",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Fallopian tube cancer",
"criterion": "fallopian tube cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Initial response to platinum and paclitaxel must have been one of the following: Progression or stable disease",
"criterion": "initial response to platinum and paclitaxel",
"requirements": [
{
"requirement_type": "response",
"expected_value": [
"progression",
"stable disease"
]
}
]
},
{
"exact_snippets": "Initial response to platinum and paclitaxel must have been one of the following: ... Response that lasted less than 3 months",
"criterion": "initial response to platinum and paclitaxel",
"requirements": [
{
"requirement_type": "response duration",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Initial response to platinum and paclitaxel must have been one of the following: ... Response that lasted at least 3 months, but when retreated with both agents (in combination or as single agents) disease was refractory",
"criterion": "initial response to platinum and paclitaxel",
"requirements": [
{
"requirement_type": "response duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
},
{
"requirement_type": "retreatment response",
"expected_value": "refractory"
}
]
},
{
"exact_snippets": "Measurable or evaluable disease",
"criterion": "disease measurability",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
}
]
},
{
"exact_snippets": "Evaluable disease is defined by: CA-125 at least 100 units/mL",
"criterion": "CA-125 level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 100,
"unit": "units/mL"
}
}
]
},
{
"exact_snippets": "CA-125 level must have at least doubled from baseline determination",
"criterion": "CA-125 level change",
"requirements": [
{
"requirement_type": "change",
"expected_value": "doubled from baseline"
}
]
}
]
},
{
"line": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST or ALT no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No New York Heart Association Class III or IV heart disease No myocardial infarction within last 6 months No congestive heart failure No unstable angina No clinically significant pericardial effusion or arrhythmia Neurology: No current peripheral neuropathy of any etiology that is greater than grade 1 Other: No active serious infection or other serious underlying medical condition No prior significant allergic reactions to drugs containing Cremophor, such as teniposide, cyclosporin, or vitamin K Not pregnant or nursing Adequate contraception required of all fertile patients",
"criterions": [
{
"exact_snippets": "Age: 18 and over",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
},
{
"exact_snippets": "Performance status: ECOG 0-2",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "ECOG"
}
}
]
},
{
"exact_snippets": "Life expectancy: At least 3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Hematopoietic: Absolute granulocyte count at least 1,500/mm3",
"criterion": "absolute granulocyte count",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Platelet count at least 100,000/mm3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN)",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "AST or ALT no greater than 2.5 times ULN",
"criterion": "AST or ALT level",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Renal: Creatinine no greater than 2.0 mg/dL",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 2.0,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "Cardiovascular: No New York Heart Association Class III or IV heart disease",
"criterion": "New York Heart Association heart disease class",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": [
"Class III",
"Class IV"
]
}
]
},
{
"exact_snippets": "No myocardial infarction within last 6 months",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "recency",
"expected_value": {
"operator": ">",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "No congestive heart failure",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "No unstable angina",
"criterion": "unstable angina",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "No clinically significant pericardial effusion or arrhythmia",
"criterion": "clinically significant pericardial effusion or arrhythmia",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "Neurology: No current peripheral neuropathy of any etiology that is greater than grade 1",
"criterion": "peripheral neuropathy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "grade"
}
}
]
},
{
"exact_snippets": "Other: No active serious infection or other serious underlying medical condition",
"criterion": "active serious infection or other serious underlying medical condition",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "No prior significant allergic reactions to drugs containing Cremophor, such as teniposide, cyclosporin, or vitamin K",
"criterion": "significant allergic reactions to drugs containing Cremophor",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "Not pregnant or nursing",
"criterion": "pregnancy or nursing",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate contraception required of all fertile patients",
"criterion": "contraception",
"requirements": [
{
"requirement_type": "requirement",
"expected_value": "adequate contraception"
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since immunotherapy No concurrent immunotherapy Chemotherapy: Prior paclitaxel treatment must have been administered on a 3 week or greater schedule No other prior chemotherapy besides platinum and paclitaxel At least 3 weeks since acceptable chemotherapy Endocrine therapy: At least 3 weeks since hormonal therapy No concurrent hormonal therapy Radiotherapy: At least 3 weeks since radiotherapy No prior radiation to greater than 30% of bone marrow Surgery: At least 3 weeks since major surgery",
"criterions": [
{
"exact_snippets": "At least 3 weeks since immunotherapy",
"criterion": "time since immunotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "No concurrent immunotherapy",
"criterion": "concurrent immunotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Prior paclitaxel treatment must have been administered on a 3 week or greater schedule",
"criterion": "paclitaxel treatment schedule",
"requirements": [
{
"requirement_type": "schedule",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "No other prior chemotherapy besides platinum and paclitaxel",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "allowed treatments",
"expected_value": [
"platinum",
"paclitaxel"
]
}
]
},
{
"exact_snippets": "At least 3 weeks since acceptable chemotherapy",
"criterion": "time since acceptable chemotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "At least 3 weeks since hormonal therapy",
"criterion": "time since hormonal therapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "No concurrent hormonal therapy",
"criterion": "concurrent hormonal therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "At least 3 weeks since radiotherapy",
"criterion": "time since radiotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "No prior radiation to greater than 30% of bone marrow",
"criterion": "prior radiation to bone marrow",
"requirements": [
{
"requirement_type": "extent of radiation",
"expected_value": {
"operator": "<=",
"value": 30,
"unit": "%"
}
}
]
},
{
"exact_snippets": "At least 3 weeks since major surgery",
"criterion": "time since major surgery",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}